State-of-the-art disease-modifying osteoarthritis drugs

Area of Science:

• Orthopedics and Rheumatology
• Biomedical Engineering
• Pharmacology

Background:

• Osteoarthritis (OA) management has advanced symptomatically, but disease-modifying drugs (DMDs) are in early development.
• Understanding OA's complex pathways offers targets, yet measuring disease progression hinders drug assessment.
• Current limitations in assessing OA progression impede the development of effective disease-modifying osteoarthritis drugs.

Purpose of the Study:

• To review the current state and future directions of disease-modifying osteoarthritis drugs.
• To highlight advancements in imaging and biomarker technologies for OA assessment.
• To discuss the potential for OA prevention, retardation, and reversal.

Main Methods:

• Review of recent literature on OA pathophysiology, drug development, and assessment techniques.
• Analysis of novel imaging modalities including advanced plain radiography, MRI, and gadolinium-enhanced MRI.
• Investigation into noninvasive biomarkers for detecting structural changes in OA.

Main Results:

• Symptomatic OA treatments have improved, but true disease modification remains a challenge.
• Advanced imaging techniques offer more reproducible methods for tracking OA progression.
• Noninvasive biomarkers are under intense investigation for their potential to reflect structural changes.
• Early studies suggest disease modification, including prevention, retardation, and reversal, may be achievable.

Conclusions:

• Despite challenges in measuring disease progression, advancements in imaging and biomarkers are crucial for developing disease-modifying osteoarthritis drugs.
• The potential exists to move beyond symptomatic treatment towards therapies that can prevent, slow, or even reverse osteoarthritis.
• Continued research into OA pathophysiology and assessment tools is vital for future therapeutic breakthroughs.